Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Current Deferred Revenue (2018 - 2025)

Health Catalyst's Current Deferred Revenue history spans 8 years, with the latest figure at $56.1 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 5.3% year-over-year to $56.1 million; the TTM value through Dec 2025 reached $56.1 million, up 5.3%, while the annual FY2025 figure was $56.1 million, 5.3% up from the prior year.
  • Current Deferred Revenue reached $56.1 million in Q4 2025 per HCAT's latest filing, down from $58.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $71.5 million in Q1 2025 to a low of $51.6 million in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $58.5 million, with a median of $56.6 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: soared 61.01% in 2021, then fell 5.82% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $57.6 million in 2021, then dropped by 4.34% to $55.1 million in 2022, then increased by 1.27% to $55.8 million in 2023, then fell by 4.51% to $53.3 million in 2024, then increased by 5.3% to $56.1 million in 2025.
  • Per Business Quant, the three most recent readings for HCAT's Current Deferred Revenue are $56.1 million (Q4 2025), $58.8 million (Q3 2025), and $67.0 million (Q2 2025).